US44148G2049
© PR Newswire
15.01.2026
HOTH
LISTED
NASDAQ
Hoth Therapeutics Reaches Key EU Regulatory Inflection Point Advancing HT-001 Oncology Trial Toward Multi-Country Site Activation
News Preview
Positive EU regulatory conclusion achievedOncology-focused clinical programMulti-country European trial footprintClear line of sight to site activation and enrollmentNear-term regulatory and operational catalystsPositive CTIS Conclusion Positions Company for Near-Term Clinical Trial Initiation in Cancer PatientsNEW YORK, Jan. 15, 2026 /PRNewswire/...
Themefolio
Profiler
Peergroup
© PR Newswire
02.01.2026
HOTH
LISTED
NASDAQ
Hoth Therapeutics Expands Oncology Pipeline with Dual Patent Filings Establishing Novel Oncology Dermatology IP Platform
News Preview
NEW YORK, Jan. 2, 2026 /PRNewswire/ -- Hoth Therapeutics (NASDAQ: HOTH), a clinical-stage biopharmaceutical company developing innovative therapies for underserved medical needs, today announced the filing of two U.S. provisional patent applications that significantly expand the Company's intellectual property portfolio and establish a new oncolog...
Themefolio
Profiler
Peergroup
© PR Newswire
03.12.2025
HOTH
LISTED
NASDAQ
Hoth Therapeutics Issues Comprehensive Pipeline Update Highlighting Clinical Progress, Orphan-Designated HT-KIT, Advancing HT-001 Phase 2, and New GDNF Metabolic Program
News Preview
NEW YORK, Dec. 3, 2025 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused clinical-stage biopharmaceutical company, today issued a comprehensive update on its therapeutic pipeline. The Company detailed meaningful progress across HT-001, HT-KIT, HT-ALZ, and its newly launched GDNF-based metabolic program, while continuing to...
Themefolio
Profiler
Peergroup
Worth to know
20.10.2025
Short Selling Radar
USA, Europe, Asia
Track Short Selling Activities worldwide
Knowing what matters
Leerverkaufsstatistiken, Hedge-Fund Aktivitäten und viele weitere nutzerwertige Informationen benutzerfreundlich aufbereitet
© PR Newswire
01.12.2025
HOTH
LISTED
NASDAQ
Hoth Therapeutics to Present at Noble Capital Markets 21st Annual Emerging Growth Equity Conference, December 2-3, 2025
News Preview
NobleCon is the preeminent showcase of small and microcap companiesNEW YORK, Dec. 1, 2025 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient focused biopharmaceutical company, today announced that Robb Knie, Chief Executive Officer, is scheduled to present at the Noble Capital Markets 21st Annual Emerging Growth Equity Conference in...
Themefolio
Profiler
Peergroup
Swarmalpha i/o · The Event Futures Prediction X
20.10.2025
© PR Newswire
20.11.2025
HOTH
LISTED
NASDAQ
Hoth Therapeutics Accepted Into NVIDIA Connect Program, Expanding Its AI and Accelerated Computing Capabilities
News Preview
NEW YORK, Nov. 20, 2025 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a clinical-stage biopharmaceutical company focused on developing breakthrough therapeutics today announced that it has been officially accepted into the NVIDIA Connect Program, a global initiative supporting innovative software and te...
Themefolio
Profiler
Peergroup
© PR Newswire
27.10.2025
HOTH
LISTED
NASDAQ
Hoth Therapeutics Launches VA-Backed Study of Novel GDNF Weight Loss Therapy Targeting Obesity and Fatty Liver Disease
News Preview
Collaborative program with the U.S. Department of Veterans Affairs aims to validate GDNF as a first-in-class biologic for obesity and hepatic health.
NEW YORK, Oct. 27, 2025 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ:...
Themefolio
Profiler
Peergroup
© PR Newswire
21.10.2025
HOTH
LISTED
NASDAQ
Hoth Therapeutics Reports FDA Orphan Drug Designation and Strong Preclinical Data for HT-KIT in Rare c-KIT-Driven Cancers
News Preview
>80% KIT knock-down and significant tumor-volume reduction in systemic mastocytosis and GIST models; GLP-validated bio analytics complete;
Japan Patent protects through 2039 as IND work advances.
Planned Next Steps (Near-Term):...
Themefolio
Profiler
Peergroup
© PR Newswire
08.10.2025
HOTH
LISTED
NASDAQ
Hoth Therapeutics Expands Artificial Intelligence Initiative, Selects NVIDIA AI Enterprise Platform
News Preview
Under the new entitlement agreement, Hoth Therapeutics secures annual NVIDIA AI Enterprise Essentials licenses to support its GPU-powered infrastructure, enabling advanced machine learning and neural network modeling capabilities for pharmaceutical research...
Themefolio
Profiler
Peergroup
© PR Newswire
07.10.2025
HOTH
LISTED
NASDAQ
Hoth Therapeutics CEO Robb Knie to Present at BIO-Europe in Vienna, Austria November 3-5, 2025
News Preview
Presentation to highlight advancements in Hoth's clinical pipeline, includingHT-001 for cancer-therapy-induced rash and HT-KIT, a novel oncology programtargeting KIT-driven tumors
NEW YORK, Oct. 7, 2025 /PRNewswire/ -- Hot...
Themefolio
Profiler
Peergroup
© PR Newswire
24.09.2025
HOTH
LISTED
NASDAQ
Hoth Therapeutics Expands HT-001 Development with Patent Filings Targeting Drug-Induced Hypersensitivity, Radiotherapy-Induced Rash, and MENIN Inhibitor-Associated Skin Toxicities
News Preview
MENIN inhibitors are a promising class of targeted oncology drugs in development for acute leukemias and certain solid tumors, but their use is often limited by severe dermatological side effects. HT-001 aims to address these toxicities, helping patients remain on therapy and realize the full benefit of treatment.
Key Highlights
U.S. Provisional...
Themefolio
Profiler
Peergroup
© PR Newswire
16.09.2025
HOTH
LISTED
NASDAQ
Hoth Therapeutics Issues Shareholder Update: HT-001, HT-KIT, Expanded Treasury Reserve Strategy, and VA Obesity Program Drive Strongest Position in Company History
News Preview
NEW YORK, Sept. 16, 2025 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a clinical-stage biopharmaceutical company, today announced a comprehensive shareholder update, underscoring momentum across its lead clinical programs and corporate strategy. With HT-001 advancing globally, HT-KIT achieving key validation milestones, the expansion o...
Themefolio
Profiler
Peergroup
© PR Newswire
10.09.2025
HOTH
LISTED
NASDAQ
Hoth Therapeutics Secures Key European Regulatory Milestone with EMA Submission for Phase II Trial of HT-001 in Cancer Patients Suffering from EGFRi-Induced Skin Toxicities
News Preview
NEW YORK, Sept. 10, 2025 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a clinical-stage biopharmaceutical innovator, today announced it has submitted its Clinical Trial Application (CTA) to the European Medicines Agency (EMA) to expand its ongoing Phase II trial of HT-001, a novel topical therapeutic for skin toxicities associated with...
Themefolio
Profiler
Peergroup
Advertisment
20.10.2025
© PR Newswire
04.09.2025
HOTH
LISTED
NASDAQ
Hoth Therapeutics Taps Lantern Pharma's PredictBBB.ai Platform -- Breakthrough AI With 94% Accuracy Driving Next-Gen Drug Development
News Preview
NEW YORK, Sept. 4, 2025 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a clinical-stage biopharmaceutical innovator, today announced that it is leveraging Lantern Pharma's breakthrough PredictBBB.ai™ platform, a next-generation artificial intelligence (AI) tool with 94% accuracy in predicting blood-brain barrier permeability. This adopti...
Themefolio
Profiler
Peergroup
© PR Newswire
02.09.2025
HOTH
LISTED
NASDAQ
Hoth Therapeutics' Cancer Therapeutic HT-KIT Surpasses Preclinical Milestones With Potent Anti-Tumor Activity and GLP-Validated Bioanalytical Results, Exceeding Regulatory Standards
News Preview
NEW YORK, Sept. 2, 2025 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a clinical-stage biopharmaceutical innovator, today announced combined positive findings from multiple preclinical programs evaluating its precision antisense candidate HT-KIT, including compelling anti-tumor efficacy, a clean safety profile, and new GLP-validated bio...
Themefolio
Profiler
Peergroup
© PR Newswire
29.07.2025
HOTH
LISTED
NASDAQ
Hoth Therapeutics Announces Engagement with ICON and Expansion of Phase II Clinical Trial for HT-001 in Europe
News Preview
The Company plans to extend its Phase II trial of HT-001 in Cancer Patients with skin toxicities in European Union (EU) Countries
NEW YORK, July 29, 2025 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a clinical-stage biopharma innovator, today announced its engagement with ICON Clinical Research Limited ("ICON") to expand it's Phase II...
Themefolio
Profiler
Peergroup
© PR Newswire
22.07.2025
HOTH
LISTED
NASDAQ
Hoth Therapeutics Signs VA Research Deal to Advance GDNF as Breakthrough Therapy for Obesity and Fatty Liver - Side-by-Side Study vs. Semaglutide Begins
News Preview
NEW YORK, July 22, 2025 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a clinical-stage biopharma innovator, today announced a CRADA (Cooperative Research and Development Agreement) with the U.S. Department of Veterans Affairs and Foundation for Atlanta Veterans Education and Research (FAVER) to evaluate GDNF (glial cell-derived neurotro...
Themefolio
Profiler
Peergroup
© PR Newswire
25.06.2025
HOTH
LISTED
NASDAQ
Hoth Therapeutics (HOTH) and Silo Pharma (NASDAQ: SILO) today announced the formation of a 50/50 joint venture to develop a first-in-class GDNF-based therapy licensed from the U.S. Department of Veterans Affairs. The therapy targets obesity and fatty live
News Preview
*Hoth Therapeutics and Silo Pharma Launch Joint Venture to Commercialize VA-Invented Obesity Drug Targeting $100B+ Global Market
Exclusive License from U.S. Department of Veterans Affairs to Advance GDNF-Based Therapy for Obesity and Fatty Liver Disease
NEW YORK, June 25, 2025 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH) and Silo Pharma...
Themefolio
Profiler
Peergroup
© PR Newswire
24.06.2025
HOTH
LISTED
NASDAQ
Hoth Therapeutics HT-001 Interim Results First-in-Class Topical Therapy Preserves Cancer Treatment While Resolving Dermatologic Side Effects
News Preview
Hoth Therapeutics' HT-001 Achieves 100% Response Rate in at least one endpoint in Phase 2a Trial in PK Patients for EGFR Inhibitor-Related Skin Toxicities.
Hoth Therapeutics will host a Key Opinion Leader (KOL) event on, at 3:30PM EST to highlight recent clinical progress with HT-001, a novel topical therapeutic developed to address EGFR inhibito...
Themefolio
Profiler
Peergroup
© PR Newswire
23.06.2025
HOTH
LISTED
NASDAQ
Hoth Therapeutics to host KOL Event Spotlighting HT-001, Novel Therapy
News Preview
Developed to address EGFR inhibitor-induced skin toxicities in cancer patients
NEW YORK, June 23, 2025 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a clinical-stage biopharmaceutical company developing innovative therapies, today announced that they will host a virtual Key Opinion Leader (KOL) event on Tuesday, June 24, 2025, at 3:30P...
Themefolio
Profiler
Peergroup
© PR Newswire
18.06.2025
HOTH
LISTED
NASDAQ
Hoth Therapeutics Regains Nasdaq Compliance - Clears Key Listing Hurdle, Reaffirms Path Toward Growth
News Preview
NEW YORK, June 18, 2025 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a clinical-stage biopharmaceutical company focused on breakthrough therapies, today announced that it has regained full compliance with Nasdaq's minimum bid price requirement....
Themefolio
Profiler
Peergroup
© PR Newswire
18.06.2025
HOTH
LISTED
NASDAQ
Hoth Therapeutics Reports Positive Preclinical Safety Data for Cancer Fighting HT-KIT -- Dose-Dependent Liver Activity with No Observed Toxicity Supports IND Pathway
News Preview
HOTH ALERT: Hoth Therapeutics Reports Positive Preclinical Safety Data for HT-KIT — Dose-Dependent Activity, No Toxicity, IND on Deck
HOTH announces strong preclinical data for HT-KIT showing dose-dependent liver activity with zero observed toxicity – key milestone as the company prepares for IND filing.
Study Results:
Liver weight increased from...
Themefolio
Profiler
Peergroup
© PR Newswire
16.06.2025
HOTH
LISTED
NASDAQ
Hoth Therapeutics to Attend 2025 BIO International Convention
News Preview
NEW YORK, June 16, 2025 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a clinical-stage biopharmaceutical company, pioneering breakthrough therapies to improve the lives of patients, today announced that Robb Knie, Chief Executive Officer, is scheduled to attend the BIO International Convention, in Boston, MA, June 16-19,2025....
Themefolio
Profiler
Peergroup
© PR Newswire
12.06.2025
HOTH
LISTED
NASDAQ
Hoth Therapeutics Secures Japanese Patent for Breakthrough HT-KIT Platform Targeting Mast Cell Diseases
News Preview
Protection through 2039, ensuring long-term commercial exclusivity.
NEW YORK, June 12, 2025 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a clinical-stage biopharmaceutical company developing innovative therapies, today announced that they have obtained Japan Country Patent No. 7677628 for the HT-KIT platform. The patent was officially...
Themefolio
Profiler
Peergroup
© PR Newswire
12.06.2025
HOTH
LISTED
NASDAQ
Hoth Therapeutics Secures Japanese Patent for Breakthrough HT-KIT Platform Targeting Mast Cell Diseases
News Preview
Protection through 2039, ensuring long-term commercial exclusivity.
NEW YORK, June 12, 2025 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a clinical-stage biopharmaceutical company developing innovative therapies, today announced that they have obtained Japan Country Patent No. 7677628 for the HT-KIT platform. The patent was officially...
Themefolio
Profiler
Peergroup
© PR Newswire
11.06.2025
HOTH
LISTED
NASDAQ
Hoth Therapeutics Launches Expanded Access Initiative for HT-001, Offering Critical Relief to Cancer Patients Facing Severe Skin Toxicities
News Preview
Premier Research to support submission of an Expanded Access Program (EAP) application.
This move positions Hoth to offer compassionate access to HT-001 for cancer patients suffering from painful and debilitating skin toxicities caused by epidermal growth factor receptor (EGFR) inhibitor therapies—an area of high unmet medical need.
"We're seeing...
Themefolio
Profiler
Peergroup
© PR Newswire
05.06.2025
HOTH
LISTED
NASDAQ
Hoth Therapeutics to Spotlight HT-001 in Investor-Focused KOL Event Addressing Breakthrough Combating Cancer Treatment Skin Toxicities
News Preview
Company Expands IP Portfolio While Advancing Clinical Innovation in Oncology Supportive Care
Case Study and Interim Clinical Trial Results Will Be Discussed
NEW YORK, June 5, 2025 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a clinical-stage biopharmaceutical company pioneering breakthrough therapies to improve the lives of patients, t...
Themefolio
Profiler
Peergroup
© PR Newswire
12.05.2025
HOTH
LISTED
NASDAQ
Hoth Therapeutics Reports Positive Preclinical Results for HT-KIT, a Precision Antisense Therapy Targeting Rare and Aggressive KIT-Driven Cancers
News Preview
HT-KIT dramatically suppresses tumor growth in preclinical models of GIST and systemic mastocytosis. Treatment shows potent downregulation of oncogenic KIT mutations with no observed systemic toxicity. IND filing expected early 2026, opening pathway to first-in-human trials. Preclinical Milestones:
Over 80% reduction in KIT expression in vitro us...
Themefolio
Profiler
Peergroup
© PR Newswire
17.04.2025
HOTH
LISTED
NASDAQ
Hoth Therapeutics Announces Granted Japanese Patent for Novel RNA-Based Cancer Therapy Targeting KIT Gene - Expands Global IP in Precision Oncology Platform
News Preview
Patent Grant Strengthens Hoth's RNA Therapeutics Pipeline with Broad Claims Covering KIT-Targeted Antisense Oligomers for Oncology and Immunology Applications
NEW YORK, April 17, 2025 /PRNewswire/ -- Hoth Therapeutics, Inc.(NASDAQ: HOTH), a clinical-stage biopharmaceutical company developing next-generation RNA-targeted precision therapies, today...
Themefolio
Profiler
Peergroup
© PR Newswire
15.04.2025
HOTH
LISTED
NASDAQ
Hoth Therapeutics Announces Positive Initial Data in Phase 2a Clinical Trial
News Preview
Reports 50% Reduction in Pruritus (Mean Score Dropped from 1.6 to 0.8) by Day 21 inOpen-Label Portion of CLEER HT-001 Phase 2a clinical Trial for Cancer EGFR Inhibitor-Induced Skin Toxicities
Key Interim Results (Day 1–21):
Patients experienced a 50% reduction in pruritus severity, with mean scores dropping from 1.6 on Day 1 to 0.8 by Day 21.Rapi...
Themefolio
Profiler
Peergroup
© PR Newswire
02.04.2025
HOTH
LISTED
NASDAQ
Hoth Therapeutics Collaborates with Washington University on NIH Grant Application Advancing Alzheimer's Program Using NK-1 Receptor Antagonist HT-ALZ
News Preview
NEW YORK, April 2, 2025 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused clinical-stage biopharmaceutical company, today announced its collaboration with Washington University School of Medicine in St. Louis to advance Alzheimer's disease research through a novel therapeutic strategy. The partnership centers on a recently...
Themefolio
Profiler
Peergroup
© PR Newswire
02.04.2025
HOTH
LISTED
NASDAQ
Hoth Therapeutics Announces Positive Pre Clinical Data HT-ALZ Shows Promising Breakthrough in Alzheimer's Disease Research Acute treatment with HT-ALZ led to a rapid (~15%) reduction in brain interstitial fluid Aβ levels, within 20 hours
News Preview
Results underscore the dual-action profile of HT-ALZ—impacting both pathology and symptomology.
NEW YORK, April 2, 2025 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company focused on developing innovative treatments for unmet medical needs, today announced groundbreaking preclinical data supporting the therapeutic...
Themefolio
Profiler
Peergroup
© PR Newswire
31.03.2025
HOTH
LISTED
NASDAQ
Hoth Therapeutics Receives USPTO Filing Receipt for HT-001 Formulation Patent Application, Expanding Existing Patent Coverage
News Preview
NEW YORK, March 31, 2025 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused clinical-stage biopharmaceutical company, today announced that it has received an official Filing Receipt from the United States Patent and Trademark Office (USPTO) for a new patent application related to the proprietary formulation of HT-001, the C...
Themefolio
Profiler
Peergroup
© PR Newswire
26.03.2025
HOTH
LISTED
NASDAQ
Hoth Therapeutics Advances Cancer Fighting HT-KIT Program with New Patent Filing and Preclinical Study Initiation
News Preview
NEW YORK, March 26, 2025 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company focused on developing first-in-class therapies for allergic and inflammatory diseases, today announced two major developments in the ongoing advancement of its proprietary antisense oligonucleotide (ASO) cancer fighting drug candidate, HT-...
Themefolio
Profiler
Peergroup
© PR Newswire
18.03.2025
HOTH
LISTED
NASDAQ
Hoth Therapeutics Announces Positive Preclinical Results for HT-KIT in Aggressive Cancer Gastrointestinal Stromal Tumors (GIST). HT-KIT Triggered Significant Tumor Cell Death as Early as 24 Hours Post-treatment
News Preview
New Data Demonstrates Significant Reduction in Tumor Growth and KIT Expression in Preclinical GIST Models
Induction of Tumor Cell Death – HT-KIT triggered significant tumor cell death as early as 24 hours post-treatment, while the lower dose led to delayed but substantial cell death at 72 hours. Decreased Tumor Cell Proliferation – HT-KIT treatm...
Themefolio
Profiler
Peergroup
© PR Newswire
10.03.2025
HOTH
LISTED
NASDAQ
Hoth Therapeutics Announces Plans to Submit Expanded Access Application for HT-001 to Support Cancer Patients in Need
News Preview
HT-001 is being developed to alleviate the adverse dermatological effects experienced by cancer patients undergoing epidermal growth factor receptor (EGFR) inhibitor treatments. With positive progress in ongoing clinical studies, Hoth Therapeutics aims to provide patients access to HT-001 outside of traditional clinical trials through the Expande...
Themefolio
Profiler
Peergroup
© PR Newswire
05.03.2025
HOTH
LISTED
NASDAQ
Hoth Therapeutics Announces Positive Results for HT-001 in Treating EGFR Inhibitor-Associated Papulopustular Eruptions Findings to be Presented at the American Academy of Dermatology 2025 Annual Meeting
News Preview
The data will be presented at the American Academy of Dermatology (AAD) 2025 Annual Meeting, which takes place March 7-11, 2025, highlighting HT-001 as a potential breakthrough therapy for EGFR inhibitor-induced dermatologic toxicities.
The recent case study will be highlighted that demonstrated the efficacy of HT-001 2% cream in a 59-year-old pa...
Themefolio
Profiler
Peergroup
© PR Newswire
04.03.2025
HOTH
LISTED
NASDAQ
Hoth Therapeutics Announces Positive Findings on GDNF's Potential as a Game-Changer in Obesity Treatment and Reduced Fatty Liver Disease
News Preview
Research Demonstrates GDNF's Ability to Prevent and Reverse Obesity by Enhancing Fat Metabolism and Energy ExpenditureHoth is developing this therapeutic in Partnership with the Department of Veterans AffairsKey Findings from the Study:
Protection Against High-Fat Diet-Induced Obesity – GDNF-tg mice exhibited significantly lower body weight and r...
Themefolio
Profiler
Peergroup
© PR Newswire
10.02.2025
HOTH
LISTED
NASDAQ
Hoth Therapeutics Partners with OnTargetx R&D to Advance Research for Cancer fighting HT-KIT Cancer Therapeutic
News Preview
NEW YORK, Feb. 10, 2025 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company dedicated to developing innovative therapies for unmet medical needs, today announced its collaboration with OnTargetx R&D Inc. to advance research for its cancer-fighting therapeutic, HT-KIT. This immunohistochemistry study, conducted...
Themefolio
Profiler
Peergroup
© PR Newswire
24.01.2025
HOTH
LISTED
NASDAQ
Hoth Therapeutics Regains Compliance with Nasdaq Listing Requirements
News Preview
NEW YORK, Jan. 24, 2025 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH) (the "Company" or "Hoth Therapeutics"), a biopharmaceutical company, today announced that it has received notification from the Listing Qualifications Department of The Nasdaq Stock Market LLC ("Nasdaq") that the Company has regained compliance with Nasdaq's minimum bi...
Themefolio
Profiler
Peergroup
© PR Newswire
21.01.2025
HOTH
LISTED
NASDAQ
Hoth Therapeutics Expands Intellectual Property Portfolio with Acquisition of New Patent Applications
News Preview
IP will be used to pursue further indications for HT-001 Cancer Therapeutic
NEW YORK, Jan. 21, 2025 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, proudly announces advancements in its intellectual property portfolio through the acquisition and expansion of patent applications to its innovativ...
Themefolio
Profiler
Peergroup
© PR Newswire
17.01.2025
HOTH
LISTED
NASDAQ
Hoth Therapeutics to Attend Sequire Investor Summit January 21-23, 2025
News Preview
NEW YORK, Jan. 17, 2025 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced that Robb Knie, Chief Executive Officer, is scheduled to attend the Sequire Investor Summit.
To learn more...
Themefolio
Profiler
Peergroup
© PR Newswire
08.01.2025
HOTH
LISTED
NASDAQ
Hoth Therapeutics Responds to Market Rumors and Shareholder Inquiries
News Preview
The Company affirms that it has no plans for a public or private offering at this time.
Hoth's financial position remains robust, with a strong balance sheet that includes over $10 million in cash and no debt.
Hoth is pleased to report that enrollment in the HT-001 clinical trial is proceeding as planned, with all trial sites now active and enrol...
Themefolio
Profiler
Peergroup
© PR Newswire
07.01.2025
HOTH
LISTED
NASDAQ
Hoth Therapeutics Achieves Breakthrough in Phase 2a Trial: HT-001 Delivers 100% Success in Combating Cancer Treatment Skin Toxicities
News Preview
Highlights:
100% of Patients in Cohort 1 Achieve Primary Efficacy EndpointNo Treatment-Related Adverse Effects ObservedPreserves Cancer Treatment Efficacy with Zero Dose ReductionsNEW YORK, Jan. 7, 2025 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a leading biopharmaceutical company focused on patient-centric solutions, today shared en...
Themefolio
Profiler
Peergroup
© PR Newswire
26.12.2024
HOTH
LISTED
NASDAQ
Hoth Therapeutics Enters Partnership with the Department of Veterans Affairs to Develop Obesity Treatment
News Preview
Hoth Therapeutics Enters Exclusive Patent License Agreement with VA and Emory University
Hoth Also Expands Its' Intellectual Property to Further Its' Market Opportunity for HT-001
NEW YORK, Dec. 26, 2024 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company focused on developing innovative therapies, today announced...
Themefolio
Profiler
Peergroup
© PR Newswire
20.11.2024
HOTH
LISTED
NASDAQ
Hoth Therapeutics Board of Directors Approves Bitcoin as Treasury Reserve Asset
News Preview
NEW YORK, Nov. 20, 2024 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient focused biopharmaceutical company, today announced that the Company's Board of Directors approved the purchase of up to $1 million in Bitcoin....
Themefolio
Profiler
Peergroup
© PR Newswire
29.10.2024
HOTH
LISTED
NASDAQ
Hoth Therapeutics Announces Update on Cancer Therapeutic HT-KIT Results Suggesting the Treatment Effectively Inhibited Tumor Growth in Preclinical Treatment Study
News Preview
NEW YORK, Oct. 29, 2024 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a clinical-stage biopharmaceutical company dedicated to developing new generation therapies for unmet medical needs, is excited to announce highly promising early data from a preclinical study of its latest cancer treatment. The preliminary results demonstrate that th...
Themefolio
Profiler
Peergroup
© PR Newswire
15.10.2024
HOTH
LISTED
NASDAQ
Hoth Therapeutics Awarded Key US Patent for Groundbreaking Alzheimer's Treatment and Prepares for Clinical Trials of HT-ALZ with Formulation Now Underway
News Preview
NEW YORK, Oct. 15, 2024 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a clinical-stage biopharmaceutical company focused on developing innovative treatments, is proud to announce the granting of a U.S. patent for its pioneering Alzheimer's treatment, HT-ALZ. This milestone patent secures the company's intellectual property rights to its...
Themefolio
Profiler
Peergroup
© PR Newswire
17.09.2024
HOTH
LISTED
NASDAQ
Hoth Therapeutics Announces Promising Preclinical Results for Alzheimer's Drug HT-ALZ
News Preview
Early observations suggest that the vehicle-treated Alzheimer's mice exhibit a larger population of reactive astrocytes, while the HT-ALZ treated groups show fewer reactive astrocytes, pointing to a potential breakthrough in the treatment of Alzheimer's.
NEW YORK, Sept. 17, 2024 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmac...
Themefolio
Profiler
Peergroup
© PR Newswire
05.09.2024
HOTH
LISTED
NASDAQ
Hoth Therapeutics Announces Expansion of Clinical Sites for HT-001 Phase 2a Trial
News Preview
Dana-Farber Cancer Institute in Boston, MA and Montefiore Medical Center in New York, NY Join Clinical Trial
NEW YORK, Sept. 5, 2024 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, today announced today that it has received Institutional Review Board approval from the Montefiore Medical Center...
Themefolio
Profiler
Peergroup
© PR Newswire
05.09.2024
HOTH
LISTED
NASDAQ
Hoth Therapeutics Announces Positive Data from First-of-its-Kind Human Patient Treatment of EGFRI-Associated Skin Toxicities with HT-001
News Preview
Cancer Patient Ceased Treatment After One Week Due to Rapid Success
In the reported case, the patient, a 59-year-old female undergoing treatment at George Washington University for metastatic breast cancer, experienced significant improvement in symptoms just one week after initiating HT-001 therapy. Due to the swift resolution of lesions and th...
Themefolio
Profiler
Peergroup
© PR Newswire
15.08.2024
HOTH
LISTED
NASDAQ
Hoth Therapeutics and Aronnax Inc. Enter Master Services Agreement For HT-KIT Cancer Therapeutic
News Preview
Aronnax to Determine the Maximum-Tolerated Dose (MTD) Post Intravenous Injection Followed by a Dose Range-Finding Phase of Hoth's Orphan Drug HT-KIT
NEW YORK, Aug. 15, 2024 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, today announced that it has entered into a Master Services Agreement with...
Themefolio
Profiler
Peergroup
© Newsfile
22.09.2021
HOTH
LISTED
NASDAQ
Hoth Therapeutics, Inc.: Invitation to the Benzinga Healthcare Small Cap Conference
News Preview
Detroit, Michigan--(Newsfile Corp. - September 22, 2021) - Hoth Therapeutics, Inc. (NASDAQ: HOTH) will be presenting at the Benzinga Healthcare Small Cap Conference taking place on September 29-30, 2021. We invite our shareholders and all interested parties to explore healthcare small cap investment opportunities through two days of networki...
Themefolio
Profiler
Peergroup
Long/Short | Fractionals | Margin | Hedge · 4 powerful Trading App | MT4.MT5.ACTIVTRADER | TradingViewplus
More information, click here
More sector specific news
Your Press Release is missing or you want share news over GICS11? Drop us a line.
